Arcellx Valuation
| ACLX Stock | USD 71.68 0.10 0.14% |
At this time, the firm appears to be undervalued. Arcellx shows a prevailing Real Value of $82.49 per share. The current price of the firm is $71.68. Our model approximates the value of Arcellx from analyzing the firm fundamentals such as return on equity of -0.23, and Profit Margin of (0.99) % as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Arcellx's price fluctuation is very steady at this time. Calculation of the real value of Arcellx is based on 3 months time horizon. Increasing Arcellx's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Arcellx is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arcellx Stock. However, Arcellx's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 71.68 | Real 82.49 | Hype 71.21 | Naive 76.64 |
The intrinsic value of Arcellx's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Arcellx's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Arcellx helps investors to forecast how Arcellx stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arcellx more accurately as focusing exclusively on Arcellx's fundamentals will not take into account other important factors: Arcellx Total Value Analysis
Arcellx is presently expected to have valuation of 3.4 B with market capitalization of 3.94 B, debt of 54.08 M, and cash on hands of 306.99 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Arcellx fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.4 B | 3.94 B | 54.08 M | 306.99 M |
Arcellx Investor Information
About 98.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.0. Arcellx had not issued any dividends in recent years. Based on the key measurements obtained from Arcellx's financial statements, Arcellx is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Arcellx Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arcellx has an asset utilization ratio of 15.17 percent. This suggests that the Company is making $0.15 for each dollar of assets. An increasing asset utilization means that Arcellx is more efficient with each dollar of assets it utilizes for everyday operations.Arcellx Ownership Allocation
The majority of Arcellx outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arcellx to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arcellx. Please pay attention to any change in the institutional holdings of Arcellx as this could imply that something significant has changed or is about to change at the company.Arcellx Profitability Analysis
The company reported the previous year's revenue of 107.94 M. Net Loss for the year was (107.35 M) with loss before overhead, payroll, taxes, and interest of (49.16 M).About Arcellx Valuation
Our relative valuation model uses a comparative analysis of Arcellx. We calculate exposure to Arcellx's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Arcellx's related companies.Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland. Arcellx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 78 people.
Arcellx Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 53.6 M |
Additional Tools for Arcellx Stock Analysis
When running Arcellx's price analysis, check to measure Arcellx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcellx is operating at the current time. Most of Arcellx's value examination focuses on studying past and present price action to predict the probability of Arcellx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcellx's price. Additionally, you may evaluate how the addition of Arcellx to your portfolios can decrease your overall portfolio volatility.